BioSymetrics appoints John Baldoni to its strategic advisory board

BioSymetrics, a phenomenon-driven AI drug discovery company, today announced that John Baldoni will join its Strategic Advisory Board. John is a pharmaceutical industry veteran with over 40 years of experience including 29 years at GSK. As an advisor to BioSymetrics, he will support the advancement of the company’s target discovery platform and drug discovery programs, as well as advise on pharmaceutical partnership deals.
An early proponent of AI applications to accelerate drug discovery, John searches for promising startups for advisory roles, which led him to BioSymetrics. John said, “I’m always looking for companies that can generate large amounts of relevant and consistent data to increase the chances of getting a drug to market faster and improving patient outcomes. What makes BioSymetrics compelling is the ability to connect their clinical and genomic research directly to their biological assays for insight. Their process is poised to improve translation of potential targets and reduce downstream clinical trial failures.”
John added, “Ultimately, we need to change how targets are assessed and tracked — first in silico — and BioSymetrics is taking that approach with its phenomenon-driven target discovery platform.”
John has been involved in the research and development of many commercial drugs. Previously, he was SVP platform technology and science at GSK, SVP in silico drug discovery at GSK and CTO of Valo Health. John conceived, founded and is currently CEO of the ATOM Consortium, a public-private partnership advancing drug discovery through a pre-competitive platform that integrates diverse data and high-performance computing.
“John is a rare individual who can combine decades of experience in the pharmaceutical industry with a passion for continuous innovation and improvement using technology. We are excited to have him join BioSymetrics as an advisor,” said Anthony Iacovone, co-founder and CEO of BioSymetrics. “His advice is greatly appreciated as we continue to advance the development of our Elion platform and our initial discovery programs for diseases with critical unmet needs.”